MX384386B - Uso de células mononucleares de sangre periférica en la fabricación de una composición útil en un método de fertilización in vitro. - Google Patents

Uso de células mononucleares de sangre periférica en la fabricación de una composición útil en un método de fertilización in vitro.

Info

Publication number
MX384386B
MX384386B MX2014006234A MX2014006234A MX384386B MX 384386 B MX384386 B MX 384386B MX 2014006234 A MX2014006234 A MX 2014006234A MX 2014006234 A MX2014006234 A MX 2014006234A MX 384386 B MX384386 B MX 384386B
Authority
MX
Mexico
Prior art keywords
peripheral blood
mononuclear cells
blood mononuclear
patient
vitro fertilization
Prior art date
Application number
MX2014006234A
Other languages
English (en)
Other versions
MX2014006234A (es
Inventor
Alexander Feskov
Irina Feskova
Stanislav Zhilkov
Ievgeniia Zhylkova
Original Assignee
Mezadata Medical Ip Holding Llp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mezadata Medical Ip Holding Llp filed Critical Mezadata Medical Ip Holding Llp
Publication of MX2014006234A publication Critical patent/MX2014006234A/es
Publication of MX384386B publication Critical patent/MX384386B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/42—Gynaecological or obstetrical instruments or methods
    • A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
    • A61B17/435—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for embryo or ova transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D19/00—Instruments or methods for reproduction or fertilisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D19/00—Instruments or methods for reproduction or fertilisation
    • A61D19/04—Instruments or methods for reproduction or fertilisation for embryo transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/412—Contraceptive or sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/31—Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere un método de la fertilización in vitro en donde el embrión es implantado en el útero de una paciente de sexo femenino al menos dos, y preferiblemente de tres a doce meses después de que los óvulos son extraídos de la paciente con el fin de reducir el efecto del rechazo autoinmune del embrión por el sistema autoinmune de la paciente e incrementar la probabilidad y éxito del embarazo, y en donde antes de la implantación del embrión, el endometrio en el útero es preparado para la implantación del embrión por medio de la introducción de las células mononucleares de sangre periférica (PBMCs) en el útero. El procedimiento se combina con técnicas de criopreservación para preservar los ovocitos o los embriones producidos por FIV de la paciente.
MX2014006234A 2011-11-23 2012-11-21 Uso de células mononucleares de sangre periférica en la fabricación de una composición útil en un método de fertilización in vitro. MX384386B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161629651P 2011-11-23 2011-11-23
US13/655,257 US10271876B2 (en) 2011-11-23 2012-10-18 Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells
PCT/US2012/066258 WO2013078312A1 (en) 2011-11-23 2012-11-21 Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells

Publications (2)

Publication Number Publication Date
MX2014006234A MX2014006234A (es) 2015-02-10
MX384386B true MX384386B (es) 2025-03-14

Family

ID=48470292

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006234A MX384386B (es) 2011-11-23 2012-11-21 Uso de células mononucleares de sangre periférica en la fabricación de una composición útil en un método de fertilización in vitro.

Country Status (14)

Country Link
US (4) US10271876B2 (es)
EP (1) EP2782993A4 (es)
KR (1) KR20140113917A (es)
CN (2) CN110295143A (es)
AU (2) AU2012340647A1 (es)
BR (1) BR112014012533A2 (es)
CA (2) CA2856860C (es)
EA (1) EA038427B1 (es)
IL (2) IL232784A0 (es)
MD (1) MD4526C1 (es)
MX (1) MX384386B (es)
UA (1) UA143229U (es)
WO (1) WO2013078312A1 (es)
ZA (1) ZA201404498B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3037101B1 (en) 2014-12-22 2019-03-06 Ferring B.V. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
WO2018044789A1 (en) * 2016-08-29 2018-03-08 Progena, Inc. Autologous somatic stem cell therapy, method of controllable preparation of therapeutic composition and procedure of adaptive treatment of ivf patient
CN110361534B (zh) * 2018-03-26 2023-11-03 山大生殖研发中心有限公司 评估胚胎和预测体外受精成功率的化学标记物和其应用
RU2714124C1 (ru) * 2019-06-24 2020-02-12 Галина Александровна Суханова Способ проведения экстракорпорального оплодотворения
AU2020371899A1 (en) * 2019-10-25 2022-05-19 Intellexon Gmbh HLA class I molecules in in vitro fertilization and further medical implications
US20230154608A1 (en) * 2021-11-17 2023-05-18 Optum, Inc. Machine learning techniques for predictive endometriosis-based prediction
KR102599957B1 (ko) 2022-11-16 2023-11-09 주식회사 코스모스웨일 보조생식술 성공률 향상을 위한 배아이식용 배양액 조성물 및 이의 제조 방법
CN115927177A (zh) * 2022-12-29 2023-04-07 国纳之星(上海)纳米科技发展有限公司 一种提取并分离猕猴外周血单个核细胞的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL56342A (en) 1978-12-29 1982-05-31 Zer Tamar Method and means for determining human chorionic gonadotropin in urine
US4725579A (en) 1985-02-21 1988-02-16 Serono Laboratories, Inc. Method of in vitro fertilization by a unique combination of gonadotropins
ATE142695T1 (de) 1989-01-10 1996-09-15 Amrad Corp Ltd Leukämiehemmender faktor aus vieharten und seine verwendung zur verbesserung der implantation und der entwicklung von embryonalen zellen
AU8505398A (en) 1997-07-23 1999-02-16 Northeastern University Methods for enhancing or reducing preimplantation embryo survival rates
US6927034B2 (en) 1998-02-03 2005-08-09 The Trustees Of Columbia University In The City Of New York Methods for detecting trophoblast malignancy by HCG assay
AUPP421298A0 (en) 1998-06-19 1998-07-09 Fertilitescentrum Ab Method and medium for in vitro culture of human embryos
JP2003517276A (ja) * 1998-11-30 2003-05-27 アイ・ブイ・エフ・サイエンシイズ・コロラド・インコーポレーテツド 体外受精のための系及び連続的培養液
WO2001036589A2 (en) * 1999-11-17 2001-05-25 University Of Rochester Human ex vivo immune system
CA2457849A1 (en) 2001-09-12 2003-03-20 Applied Research Systems Ars Holding N.V. Use of hcg in controlled ovarian hyperstimulation
NZ518163A (en) * 2002-04-05 2005-04-29 Kiwi Ingenuity Ltd Embryo modified with a glycolipid to enhance implantation into the endometrium
JP2005529609A (ja) 2002-06-17 2005-10-06 ケベンハウンス・アムツ・シゲフス・ハーレウ 体外受精
EP1581637A4 (en) 2002-11-07 2007-04-25 Univ Chicago MATERIALS AND METHODS WITH HUMAN STEM CELLS
JP3762975B2 (ja) 2003-03-18 2006-04-05 学校法人慶應義塾 単球由来多能性細胞ｍｏｍｃ
CA2553673A1 (en) 2003-08-28 2005-03-10 Reprocure, Llc Method for determining embryo quality
US20050118363A1 (en) * 2003-09-26 2005-06-02 Fuji Photo Film Co., Ltd. Heat transfer recording material
AU2005228201A1 (en) * 2004-03-25 2005-10-13 Community Hospitals Of Indiana, Inc. Cryopreservation media
US20050241013A1 (en) * 2004-04-22 2005-10-27 Geoffrey Sher Unique use of sHLA-G obtained in soluble form from JEG-3 cell line, by purification by PCR, HPLC, or any other techniques, as well as in other forms, as an implantation promoting agent when added to embryo culture and/or to the media in which embryos are transferred to the uterus following in vitro fertilization
DK1765085T3 (en) 2004-05-17 2015-10-05 Gen Hospital Corp Compositions comprising female germline stem cells and methods of use thereof
EP1765987A4 (en) 2004-06-11 2008-05-07 Kiwi Ingenuity Ltd ENZYMATIC MODIFICATION OF CELL SURFACE ANTIGEN H BY GLYCOSYL TRANSFERASES
WO2007008377A1 (en) * 2005-07-06 2007-01-18 University Of Tennessee Research Foundation Oocytes derived from ovarian culture initially containing no oocytes
US8183214B2 (en) * 2005-09-21 2012-05-22 Kode Biotech Limited Cell surface coating with hyaluronic acid oligomer derivative
GB0601746D0 (en) * 2006-01-27 2006-03-08 Novocellus Ltd Cryopreservation method
WO2008148105A1 (en) * 2007-05-25 2008-12-04 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
US20100239539A1 (en) * 2009-03-23 2010-09-23 Sing George L Methods for promoting differentiation and differentiation efficiency
US9815124B1 (en) 2016-03-22 2017-11-14 Flamur Tulovic Hole saw with threadably removable portion

Also Published As

Publication number Publication date
NZ807980A (en) 2024-09-27
IL276077A (en) 2020-08-31
US11957384B2 (en) 2024-04-16
EA038427B1 (ru) 2021-08-27
MX2014006234A (es) 2015-02-10
KR20140113917A (ko) 2014-09-25
AU2018203649B2 (en) 2020-10-08
CA2856860A1 (en) 2013-05-30
CN110295143A (zh) 2019-10-01
CA3079719A1 (en) 2013-05-30
IL232784A0 (en) 2014-07-31
AU2018203649A1 (en) 2018-06-07
US20190110813A1 (en) 2019-04-18
BR112014012533A2 (pt) 2017-06-06
US20220039834A1 (en) 2022-02-10
US11185348B2 (en) 2021-11-30
US10271876B2 (en) 2019-04-30
CN104126004A (zh) 2014-10-29
UA143229U (uk) 2020-07-27
EA201490996A1 (ru) 2015-02-27
EP2782993A1 (en) 2014-10-01
US20130172666A1 (en) 2013-07-04
MD20140060A2 (ru) 2014-11-30
CA2856860C (en) 2020-07-07
AU2012340647A1 (en) 2014-06-19
MD4526B1 (ro) 2017-11-30
ZA201404498B (en) 2015-08-26
MD4526C1 (ro) 2018-09-30
EP2782993A4 (en) 2015-04-15
WO2013078312A1 (en) 2013-05-30
US20240268863A1 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
MX384386B (es) Uso de células mononucleares de sangre periférica en la fabricación de una composición útil en un método de fertilización in vitro.
MX2012004881A (es) Metodos para reprogramar células y sus usos.
CU24495B1 (es) Compuestos que expanden las células hematopoyéticas y método ex vivo para expandir las células hematopoyéticas
ES2721180T3 (es) Productos terapéuticos usando células adiposas y secreciones celulares
CO6761392A2 (es) Administración de proteínas a partir de microportadores de células madre
BR112012010750A2 (pt) sistema de armazenamento de células-tronco germinativas humanas
DK2049906T3 (da) Assay og kit til bestemmelse af implantationssucces ved kunstig befrugtning
CL2012001320A1 (es) Construccion de expresion aislada que comprende un promotor de construcciones de esterilidad por via materna, una secuencia de polinucleotidos capaz de extirpar células germinales primordiales y una región no traducida 3' (utr) específica de la célula germinal; metodo para producir una hembra que pone fin al linaje.
JP6866286B2 (ja) 海産魚類の卵巣の維持方法及び培養液の調整方法、並びに海産魚類の卵又は受精卵の生産方法
Olugbenga et al. Semen characteristics and sperm morphological studies of the West African Dwarf Buck treated with Aloe vera gel extract
Gaviraghi et al. Minimum number of spermatozoa per dose in Mediterranean Italian buffalo (Bubalus bubalis) using sexed frozen semen and conventional artificial insemination
MX2022003039A (es) Metodo de seleccion de donantes universales para identificar donantes de celulas nk.
Rola et al. Assisted reproductive technology in neotropical deer: A model approach to preserving genetic diversity
MX2020011406A (es) Metodos para aumentar el progreso genetico en una linea o raza de cerdo con celulas de esperma seleccionadas por sexo.
EA202191332A1 (ru) Метод экстракорпорального оплодотворения с отсрочкой переноса эмбриона и использованием мононуклеарных клеток периферической крови
Sanchez et al. Repeated hormonal treatment and laparoscopic ovum pick-up followed by in vitro embryo production in goats raised in the tropics
Khawaskar et al. Seasonal variation in physico-morphological and functional characteristics of semen of Surti buffalo bulls and their interrelationships
MX2021012314A (es) Procedimiento de trasplante celular minimamente invasivo para inducir el desarrollo de organogenesis in vivo.
RU2018114660A (ru) Применение циклического трипептида для улучшения клеточного энергетического метаболизма
CN105483079A (zh) 基于体外受精的小鼠微生物净化方法
KR101501209B1 (ko) Nutlin-3a를 함유하는 정자의 수태능력 조절용 조성물 및 Nutlin-3a를 함유하는 피임용 약학조성물
Morita et al. Clinical application of Hg-free piezo-ICSI using fluorinert
Check et al. A case whose outcome is consistent with the possibility that if slow embryo cleavage is related to a male factor the prognosis is far greater than if it was related to an egg factor
RU2012146207A (ru) Способ создания репродуктивных маточных стад осетровых рыб
EP4450613A4 (en) Mammalian sperm preparation method, artificial insemination method, and in-vitro fertilization method